Enflonsia (clesrovimab-cfor, anti-RSV monoclonal antibody)
Prevention of RSV lower respiratory tract disease in infants during their first RSV season. Pediatric infectious disease (RSV prevention).
About Enflonsia
Enflonsia (clesrovimab) is manufactured by Merck and was approved by the US FDA in 2025 for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season. It is a single pre-season intramuscular dose, not a chronic medication.
The molecule is a long-acting monoclonal antibody that binds the RSV fusion (F) protein, blocking viral entry into respiratory epithelial cells. Enflonsia sits in the same therapeutic class as nirsevimab (Beyfortus) and the older palivizumab (Synagis) and is used for paediatric infectious disease prophylaxis rather than treatment of an established infection.
Enflonsia may be accessible to international patients through Named Patient Program or personal-import pathways where it is not yet locally registered.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Enflonsia
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Enflonsia for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Enflonsia is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Enflonsia in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Enflonsia
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.